Teva Vs Novartis Stock

last updated on

Teva Vs Novartis Stock

Teva Vs. Novartis: Which Pharmaceutical Stock Is Better?

Teva Pharmaceutical Industries and Novartis AG are two big names in the pharma sector. For those who want exposure to the pharma sector, it can often be difficult to choose between Novartis and Teva.

To pick the winner between these two, we will have to take a deep dive into the numbers of Novartis and Teva. Only after that, we can make an educated decision on which pharma stock is better.

Novartis

Novartis is a big name in the pharmaceutical world. They are mostly involved in treatments for complex diseases. These treatments offer high margins for Novartis. The company is also a leader when it comes to research and finding treatments for different complex diseases.

The company focuses on different areas such as neuroscience, oncology, and cardiovascular health. To put things into perspective, Novartis products are present in 118 countries. They also have 77K employees, which makes it a global healthcare giant.

In FY 2025, the revenue of Novartis was $56.7 billion. This means a revenue growth of 10% when compared with the last year. The net income for the same period was $14 billion. The balance sheet shows the debt-to-equity ratio of Novartis is 0.8x.

Teva Pharmaceutical

Teva Pharmaceutical makes generic and innovative medicines. The products from Teva Pharmaceutical are available in 57 different markets.

The company has a concentrated customer base. It has to rely on a select group of wholesalers and retail chains to drive most of its sales. This adds a layer of risk for Teva Pharmaceutical.

The FY 2025 revenue of Teva Pharmaceutical was $17.3 billion with a growth rate of 4.9%. The company was reporting net losses for several years, but that changed this year. The report shows Teva Pharmaceutical had a net income of $1.4 billion.

Which Pharma Stock Is Better?

The biggest challenge faced by Novartis is patent expirations. Once that happens, cheaper versions of the drugs will be available in the market. This means the company will no longer be able to sell at high margins.

Teva also faces challenges from the U.S. Inflation Reduction Act. This act could lower the prices of the products made by Novartis. The company is also involved in various legal and compliance matters.

With all things considered, Novartis is the better stock in the pharma sector. It has better profitability and is a much bigger company than Teva.

Trending Stories